Pricing
  1. US-listed companies
  2. Ampio Pharmaceuticals, Inc.
  3. Raw

Ampio Pharmaceuticals, Inc.【AMPE】

Market cap
$317.9K
P/E ratio
SummaryFinancials
Back to summarized table
Dec 31,
2011		Dec 31,
2012		Dec 31,
2013		Dec 31,
2014		Dec 31,
2015		Dec 31,
2016		Dec 31,
2017		Dec 31,
2018		Dec 31,
2019		Dec 31,
2020		Dec 31,
2021		Dec 31,
2022		Dec 31,
2023
Net loss---24,008,558-39,048,772-33,713,917-19,163,629-51,891,94534-13,630,000-15,894,000-17,075,000-16,337,000-8,632,000
Share-based Compensation358862744,870443,786405,000131159,000
Restricted stock award compensation, forfeitures-----------509,000-
Depreciation and amortization42,551104,947242,627439,098-1111111122,000
Long-lived assets impairment-----------2-
Right-of-use asset impairment-----------0-
Loss on sale of fixed assets--------123,176--73,000---56,000
Net gain from elimination of ARO obligation------------289,000
Accretion of asset retirement obligation------------5,000
Derivative gain-1,555,497205,768-516,840--78,038-915,141-36,218,832455-046-
Increase in insurance recovery receivable------------920,000
(Increase) decrease in prepaid expenses and other----1-80,684-18,473179,4651-571,000593,000-1,064,00051,000
Increase (decrease) in accounts payable and accrued expenses------1,095,0742-1,460,8773-2,475,0003-3,959,0001
Decrease in lease liability---------70,000-81,000-89,000-79,000-265,000
Net cash used in operating activities-9,131,662-9,715,163-19,133,157---14,624,972-11,407,947-12,138,023-15,383,000-15-14,089,000-21,128,000-8,564,000
Net cash used in investing activities-119,70515,000-1,665,239---6,844-72,325-564,276-22,000-63,000-97,000--
Proceeds from Sale of Common Stock in Connection with At The Market Equity Offering Program---------2611-98,000
Costs related to sale of common stock in connection with the "at-the-market" equity offering program---------1512,000-98,000
Costs related to the sale of common stock and warrants in connection with the registered direct offering----------232,000-
Funding of tax obligation relative to shares withheld in connection with restricted stock awards----------186,00079,000-
Net cash used in financing activities254170--41512142631-111,000-
Net change in cash and cash equivalents---------1,053,0001117-21,239,000-8,564,000
Commercial insurance premium financing agreement---------111703,000
Recognition of asset retirement obligation-----------282,000-